Evidence for a role of skull bone marrow in human chronic pain as revealed by TSPO PET imaging

Mehrbod Mohammadian[a], Nikos Efthimiou[a], Ludovica Brusaferri[a,b], Joya Cooper-Hohn[a], Minhae Kim[a], Jennifer P. Murphy[a], Zeynab Alshelh[a], Grace Grmek[a], Jack H. Schnieders[a], Courtney A. Chane[a], Thomas G. Carmichael[a], Danika Yang[a], Ciprian Catana[a], Steven M. Stufflebeam[a], Robert R. Edwards[c], Vitaly Napadow[d], Kimberly Sullivan[e], Matthias Nahrendorf[f], Jodi M. Gilman[g], and Marco L. Loggia*[a,h]

[a]Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; [b]Department of Computer Science and Digital Technology, College of Technology and Environment, London South Bank University, London, UK; [c]Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; [d]Spaulding Rehabilitation Hospital, Boston, MA, United States; [e]Department of Environmental Health, Boston University School of Public Health, Boston, MA, United States; [f]Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; [g]Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; [h]Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

*Corresponding author: Marco L. Loggia, PhD, 149 Thirteenth Street, Room 2301, Charlestown, MA 02129 (marco.loggia@mgh.harvard.edu).

Abstract

The skull bone marrow is emerging as a critical hub for neuroimmune signaling in various disorders, with the potential to reshape how we understand brain-immune interactions. However, its role in chronic pain is unknown. Using integrated positron emission tomography / magnetic resonance imaging, here we show that the levels of 18 kDa translocator (TSPO), a marker of immune cell density, is elevated in the skull bone marrow of patients with chronic pain (N=125; chronic low back pain [cLBP], N=88; knee osteoarthritis [KOA], N=37), compared to healthy controls (N=22). These elevations were very widespread, generally more pronounced for KOA than cLBP, and associated with greater pain intensity, pain interference, depression, and anxiety (all $p < 0.001$). Because TSPO is highly expressed in myeloid cells, these results associate skull bone marrow immune dysregulation with chronic pain and its associated psychological and functional impairments. These findings provide a strong rationale for investigating this previously overlooked structure, which remains largely underexplored in the context of pain.

Introduction

Located within the diploë, the layer of trabecular bone enclosed between inner and outer tables within the skull, the skull bone marrow, is increasingly recognized as a source of immune cells in health and disease[1–3]. Until recently, the central nervous system (CNS) was thought to be immunologically isolated from the rest of the body, and communication between the CNS and the immune system was thought to occur only under certain pathological conditions, when peripheral/circulating immune cells infiltrate the brain parenchyma after crossing the blood-brain barrier[4]. However, this view has been challenged by the recent discovery of ossified vascular microchannels that traverse the inner skull cortex[2]. These channels may serve as conduits for CNS-derived antigens, carried by the cerebrospinal fluid (CSF) from the brain into the skull marrow hematopoietic niche, where they signal and initiate myeloid egress. Conversely, myeloid cells can traffic from the marrow to the meninges and brain parenchyma, mediating inflammatory responses[5], as has been documented, for example, in rodent models following stroke or brain injury[3]. Crucially, studies have shown that these myeloid cells have distinct immune signatures compared to the myeloid cells supplied from the blood, especially in pathological conditions that involve neuroinflammation[5,6].

In a recent, preliminary report, we used integrated positron emission tomography/magnetic resonance imaging (PET/MRI) and the radioligand [^{11}C]PBR28, to show that the levels of the 18 kDa translocator protein (TSPO) might be elevated in the skull bone marrow in patients with migraine with visual aura[1]. While TSPO is most commonly used as an imaging marker of brain inflammation (e.g., in Alzheimer's disease[7], Parkinson's disease[8], stroke[9], traumatic brain injury[10], chronic pain conditions[11–14]), it is also highly expressed in peripheral immune cells, making it a marker of immune cell density beyond the central nervous system[15]. As such, the elevated TSPO PET signal we observed in the skull

bone marrow in individuals with migraine suggests an increased density of myeloid cells in this compartment, implicating it as a potential contributor to the pathophysiology of this disorder. Notably, subsequent reports of similar findings in neurodegenerative and psychiatric diseases such as Alzheimer's [3], stroke[3], depression[16], and autism[17], suggest that skull marrow activation – as measured in terms of TSPO PET signal elevation – is not unique to migraine, but may instead represent a more fundamental neuroimmune response shared across diverse neuroinflammatory conditions.

While the skull bone marrow is emerging as a site for neuroimmune signaling in various disorders, its involvement in chronic pain remains largely unknown. In this study, we aim to fill this gap by using TSPO PET to evaluate the role of skull bone marrow in patients with two different chronic pain conditions (i.e., chronic low back pain -cLBP- and knee osteoarthritis -KOA), and evaluate its association with the severity of pain and pain-comorbid symptoms. Given the emerging recognition of the skull bone marrow as a potentially critical hub for neuroimmune signaling, unveiling its involvement in chronic pain could pave the way for the investigation of novel mechanisms underlying persistent pain, with implications for the development of novel diagnostic and therapeutic tools.

Methods

Participants

A total of 125 patients with chronic pain (age, mean ± standard deviation: 53.10 ± 16.38 years old) were included in this study. Of these, 88 were patients with cLBP (47.32 ± 15.45 years old), recruited from two clinical trials (NCT03106740 and NCT03891264), and 37 were patients with KOA (66.59 ± 8.29 years old) who were scheduled to undergo total knee replacement surgery. The present study included only data collected prior to the initiation of interventions (pharmacological or surgical). In addition, data from 22 healthy

controls (55.68 ± 16.89 years old) were included in these analyses. All participants were adults, aged 18 years or older, and provided written informed consent for their inclusion in the respective research studies. Detailed inclusion and exclusion criteria are available in recent publications from our group regarding these patient cohorts[18,19]. All participants were genotyped for the Ala147Thr polymorphism in the *TSPO* gene, which predicts binding affinity of [^{11}C]PBR28[20,21] for its target, and only individuals with the Ala/Ala or Ala/Thr genotypes (corresponding to high-affinity and mixed-affinity binders, respectively) were included.

TSPO PET-MR imaging and image analysis

All participants underwent integrated PET/MRI sessions of 90-minute brain [^{11}C]PBR28 PET scan using a Siemens Biograph mMR scanner (Siemens Healthineers, Erlangen, Germany). A maximum of 15 mCi ([patients with chronic pain: 14.08 ± 1.32 mCi]; [healthy controls: 14.01 ± 1.73 mCi], p = 0.83) of [^{11}C]PBR28 was injected intravenously with a slow bolus over a 30–60-second period by a licensed nuclear medicine technologist. Dynamic PET scans were acquired in list mode, and static reconstructions were generated from the PET data 60-90 minutes after radiotracer injection. Image reconstruction was performed with an in-house developed framework for Correction of Motion and Brain Alignment (COMBRA) using ordered subset expectation maximization (OSEM)[22] with 21 subsets and 3 iterations, as implemented in Siemens e7 tools. Corrections for background, frame duration, and decay were applied in accordance with the manufacturer's guidelines. Alongside PET data collection, MR images were acquired, including a multi-echo T1-weighted MPRAGE sequence (TR/TE1/TE2/TE3/TE4 = 2530/1.69/3.55/5.41/7.27 ms, flip angle = 7°, voxel size = 1 mm³). These images were used for anatomical reference and to create a μ map ("pseudoCT") used for attenuation correction[23], as well as to create skull masks (see below). While previous studies have already shown an overall good agreement

between pseudoCT and CT[24,25], we performed a further, skull-focused, validation in a separate subset of participants (see eMethods) who underwent both PET/MRI and PET/CT. In these participants, skull PET uptake obtained using an MR-based pseudoCT- or CT-based attenuation correction yielded very comparable results (see Supplementary Materials), supporting the validity of our approach.

PET signal was quantified as the Standardized Uptake Value (SUV), calculated as the mean radioactivity concentration divided by the ratio of the administered dose to body weight.

Figure 1 illustrates the general workflow of the analysis pipeline. PseudoCT images, were generated from the T1-weighted MPRAGE scans[23]. As opposed to prior work that adopted on region-of-interest analysis focused on discrete skull regions[1], here we developed a pipeline to examine the entire skull using a voxel-wise approach, enabling a more comprehensive characterization of skull bone marrow and its relationships with symptom severity.

A skull mask was created by applying a heuristic threshold to isolate bone values. Any gaps between inner and outer skull layers or other inaccuracies resulting from this thresholding process were corrected by manual editing. An affine transformation matrix was calculated to co-register the PET SUV images to the structural T1-weighted image. The TSPO PET SUV image for each subject was then masked with the skull mask to produce an estimated skull PET SUV image. Additionally, to reduce contamination from brain signal in the skull PET data, all T1-weighted MR images were processed using the FreeSurfer[26] ‘recon-all’ pipeline, and the resulting brain mask was used to subtract the brain from the estimated skull PET SUV image.

To standardize the PET data across all subjects, each participant's T1-weighted MR image was registered to the MNI152 T1-weighted template using Advanced Normalization Tools (ANTs)[27]. The resulting transformation matrices and deformation field, combined with the affine co-registration matrix mentioned above, were then applied to normalize both the skull mask and the skull PET SUV maps into the standard MNI152 space. To further minimize the potential confound of brain signals, the MNI brain template was masked out from all skull masks and skull SUV maps. To improve the signal-to-noise ratio and prepare the imaging data for voxel-wise analyses, all skull SUV PET images were smoothed using a 5-mm full width at half maximum (FWHM) Gaussian kernel. A probability mask was subsequently generated in MNI space from the combined skull mask of all subjects and thresholded at 50%, ensuring that only voxels present within the core of the skull region were retained for final analyses. This study-specific skull template (Figure 1D) was used as a pre-thresholding mask in all voxel-wise analyses.

Behavioral Assessment

All participants completed the Patient-Reported Outcomes Measurement Information System 29-item (PROMIS-29) questionnaire at the time of the imaging visit. This instrument was used to assess a broad range of measures, including pain-related outcomes (pain intensity and pain interference), physical function, mental health (anxiety and depression), fatigue, sleep disturbance, and social well-being. Of note, due to a slight variation in the version of the questionnaire administered, the 'social roles' item differed in wording across participants, i.e., "ability to participate in social roles and activities" (N=37) vs "satisfaction with social roles and activities" (N=88). Given the conceptual similarity of the two formulations, we have elected to combine the data across versions for analysis. Raw scores were used to compare groups and for regression analyses against the imaging data. For added interpretability of the PROMIS-29 scores, we also computed and reported T-scores.

Statistical Analysis

The normality of the distribution of data was assessed using the Kolmogorov-Smirnov test. Continuous variables were analyzed using the student's t-test, and the Chi-square test of association was used to compare categorical measures between groups. In our main analyses, we combined all patients, irrespective of specific condition, into a 'Pain' group. For follow-up, exploratory analyses, individual pain subgroups (i.e., KOA and cLBP) were separately investigated. For PET analyses, sex (given the known sexual dimorphism in the role of immune cells in preclinical pain models[28]) and TSPO genotype (which predicts binding affinity to [^{11}C]PBR28 [20,21]) were included as covariates in the model. Additionally, because we observed a negative association between the TSPO PET signal and age (see Results), all main PET analyses were corrected for age. Statistical analyses of demographic and clinical variables were conducted using SAS version 9.4 (SAS Institute Inc, Cary, NC, USA) and R version 4.3.2. [^{11}C]PBR28 PET signal was analyzed using a voxel-wise permutation-based approach[29] implemented in FSL's FEAT GLM tool (www.fmrib.ox.ac.uk/fsl, version 6.0.51), using a cluster-forming threshold of z=3.1, and a cluster size significance threshold of p=0.05 to correct for multiple comparisons. In addition to the voxel-wise results (i.e., regression analyses), the following are presented for display purposes: 1) the average PET images for both patient and control groups; 2) the average PET images for patient subgroups split into tertiles in relation to PROMIS-29 scores. We conducted regression analyses against clinical variables only within the Pain group, and not within the healthy control group, given the overall limited dynamic range in the symptoms reported by the control group. Tertile-based cutoffs were chosen (rather than clinical thresholds or other methods) to ensure balanced signal averaging across the full range of values observed in our sample. These results were mapped onto a 3D rendering of the study-specific skull mask in the standard MNI152 space. Additionally, the average PET signal was extracted from the cluster significant in the voxel-

wise analyses, and plotted in box and scatter plots for KOA, cLBP, and HC separately, where applicable.

Results

Demographics and Clinical Characteristics

Demographic and baseline clinical data are summarized in Table 1. Patients with chronic pain and healthy controls did not significantly differ in sex, TSPO genotype distribution, or age. Although not statistically significant, the Pain group had a larger weight compared to healthy controls ([patients with chronic pain: 80.49 ± 16.43]; [healthy controls: 73.75 ± 12.96], $p = 0.07$).

As expected, patients reported higher levels of pain intensity (4.22 ± 2.03 on a 0 to 10 scale) and pain interference (9.51 ± 3.64 out of 20) compared to healthy controls. Among participants who were able to quantify the duration of their pain in years (N=110), the average reported duration was 7.82 ± 8.40 years overall, with similar values observed in the cLBP group (7.67 ± 7.80) and the KOA group (8.22 ± 9.57). Additionally, patients reported higher levels of anxiety (6.64 ± 3.05), depression (5.45 ± 2.32), fatigue (8.8 ± 3.21), and sleep disturbance (10.26 ± 3.57), but lower (i.e., worse) scores on physical function (12.86 ± 5.32) and social roles (11.54 ± 5.13), compared to the control group (p's < 0.05).

Converting the raw PROMIS-29 scores to T-scores revealed substantial interindividual variability in the severity levels, with most participants endorsing mild symptoms (T-score<60 for most domains; T-score>40 for social roles and physical function), but several reporting moderate (60≤T-score≤70 and 30≤T-score≤40, respectively) or even severe (T-score>70 and <30, respectively). The distribution of the T-scores for all domains in all participants is presented in eFigure 1. Pain interference was considered mild in 84 patients

(67.2%), moderate in 39 (31.2%), and severe in 2 (1.6%). For anxiety, 109 patients (87.2%) had mild, 14 (11.2%) had moderate, and 2 (1.6%) had severe symptoms. Depression scores showed that 117 patients (93.6%) reported mild and 8 (6.4%) reported moderate symptoms. Fatigue was mild in 112 patients (89.6%), but moderate in 13 (10.4%). For physical function, 58 patients (46.4%) had mild, 47 (37.6%) had moderate, and 20 (16%) had severe difficulty. Sleep disturbance was reported as mild by 115 patients (92%), moderate by 9 (7.2%), and severe by 1 patient (0.8%). In the domain of social roles, 77 patients (61.6%) had mild, 31 (24.8%) had moderate, and 17 (13.6%) had severe difficulty. As expected, the scores from the healthy controls were generally mild and limited in range. See Table 1 and the eResults section of the Supplementary Materials for demographic and clinical characteristics of the patient subgroups.

PET signal distribution and relation to demographic variables.

In both groups, the spatial distribution of the TSPO PET signal on average was comparable, with high signal intensity present in the lateral part of the frontal bone, the dorsomedial portion of the parietal and occipital bones, and the rostral and caudal portions of the parietal skull (Figure 2A). The PET signal was negatively correlated with age in the patient cohort, with significant clusters spanning over the parietal and frontal bones bilaterally (eFigure2). Plotting the average TSPO PET signal extracted from the regions significant in the voxel-wise analyses within the Pain group (eFigure2C) revealed a negative association with age was observed 1) in both patient subgroups independently and 2) also in healthy controls (even if this effect was not significant in voxel-wise analyses for this group). We did not observe a significant sex effect in either the patient or healthy control group.

Group differences

While the spatial distribution was comparable across groups, patients with chronic pain exhibited markedly higher TSPO PET signal across large portions of the skull compared to healthy controls, with particularly pronounced increases observed bilaterally in the frontal and parietal regions (Figure 2B). A follow-up analysis of the signal extracted from the regions with significantly elevated signal in the Pain group (Figure 2C) revealed that 1) both cLBP and KOA patient groups demonstrated a statistically significant increase in skull TSPO PET signal compared to healthy controls and that 2) KOA demonstrated the highest signal (despite their older age relative to the other groups). Voxel-wise differences between groups within the patient subgroup are presented in eResults and eFigure3.

Association with pain-related scores

To understand the clinical significance of the group differences in skull PET signal, we evaluated the association between imaging and clinical variables in the Pain group. Pain intensity and pain interference were positively and significantly correlated with the skull TSPO PET signal in the Pain group. For both variables, the effects were widespread, spanning over temporal, parietal, and occipital portions of the skull. The association with pain intensity was most prominent and widespread, with larger involvement of the frontal portions of the skull, and showed some left-sided dominance, with frontal, parietal, temporal, and occipital peaks being more prominent on the left hemisphere (Figure 3). The association between the TSPO PET signal and pain interference was less widespread but also showed some left-sided dominance, particularly in the caudal part of the parieto-occipital portion of the skull (Figure 4). Plotting the average signal extracted from the regions significant in these voxel-wise analyses within the Pain group revealed a similar association between PET signal and pain intensity or interference in both KOA and cLBP independently (Figures 3C, 4C).

For the healthy controls, these analyses were not pursued due to the generally limited dynamic range in reported symptoms in this group.

Association with other patient-reported scores

To further understand the clinical significance of the skull TSPO PET signal, we evaluated its association with the other domains of the PROMIS-29 questionnaire. We observed a positive and statistically significant correlation with the mental health domains of the PROMIS-29 questionnaire, namely anxiety and depression (Figure 5). For both domains, the association was significant primarily over the dorsomedial portions of the frontal and parietal bones, with the anxiety analysis yielding a slightly more extended cluster (Figure 5). Our analyses of the Pain group did not reveal significant correlations for other domains of the PROMIS-29 questionnaire.

Discussion

An emerging body of research[1,3,16,17] identifies the skull bone marrow as a potential key structure in the pathophysiology of many conditions, with possible implications for the development of new biomarkers and therapeutic targets for a broad range of human chronic conditions. Building on these findings, here we present evidence supporting a role for skull TSPO PET signal in human chronic pain conditions, leveraging a large patient dataset (N=125).

While the specific cellular mechanisms underlying our imaging results remain to be elucidated, one potential explanation for the elevated TSPO signal in the skull is neuroimmune crosstalk between the brain and skull bone marrow, mediated by recently identified vascular channels that directly connect these regions[2,30]. These channels may serve as conduits for 1) CNS-derived antigens, carried by the cerebrospinal fluid from the brain

into the skull marrow hematopoietic niche, where they signal and initiate myeloid egress, and 2) myeloid cells trafficking from the marrow to the meninges and brain, to mediate a neuroinflammatory response. This response has been documented, for instance, in rodents after a stroke or brain injury[3]. Recent evidence suggests that neutrophils may play a key role underlying these mechanisms. Kolabas et al. reported significantly higher TSPO RNA expression in the skull bone marrow of injured versus naïve mice, particularly within neutrophil populations[3]. This raises the possibility that neutrophils contribute to the skull TSPO PET signal observed in our studies, potentially reflecting an increased cellular density. Furthermore, our previous work has demonstrated elevated TSPO PET signal in the brains of individuals with various chronic pain conditions, including KOA and cLBP[12,13,18]. We speculate that inflammatory signals originating in the brain may propagate through the skull–meninges channels, thereby activating resident skull marrow immune cells and promoting the mobilization of myeloid cells, including neutrophils. This brain inflammation may, in turn, be sustained by persistent nociceptive input from peripheral pathology (e.g., in the joint or spine), consistent with the concept of 'neurogenic neuroinflammation' [31].

Remarkably, we found a statistically significant and positive correlation between the TSPO PET signal in the skull and the severity of pain and pain-comorbid symptoms, highlighting the potential clinical relevance of our observations. Among patients with chronic pain, elevated PET signal was associated with higher pain intensity and interference, as well as anxiety and depression. Importantly, while our main analyses were conducted with all patients in a single ‘Pain’ group, follow-up analyses revealed that comparable effects could be replicated within each patient subgroup despite the different pain etiologies (back or knee pain), indicating remarkable generalizability. Interestingly, the KOA group appeared to have the highest skull TSPO PET signal, followed by the cLBP and healthy control groups, for reasons that remain to be elucidated. The distinct spatial distribution of the skull TSPO PET

signal observed for different symptoms (i.e., anxiety, depression, and pain intensity/interference) suggests a possible disease- or state-specific topographical signature that warrants further examination.

Notably, a significant negative correlation was observed between skull TSPO signal and age in patients with chronic pain, with a similar trend seen in healthy controls. Similar findings were recently reported in patients with Alzheimer's disease[3], further underscoring the generalizability of this observation. This result is somewhat counterintuitive, as aging is generally thought to be accompanied by an increase in inflammation within the brain. However, recent evidence suggests that skull bone marrow undergoes continuous expansion in both volume and vascularization throughout adulthood[6,32]. Intriguingly, the rate of such decline in skull TSPO signal appeared qualitatively steeper for the chronic pain groups. Nevertheless, future studies with larger samples of healthy controls are needed to formally test this hypothesis.

The present study has several notable strengths, including a large sample size and the inclusion of two separate groups of chronic pain patients. However, there are several limitations. Perhaps most importantly, in this cross-sectional analysis, it is impossible to determine whether the TSPO PET signal is caused by the painful condition or precedes it. Future longitudinal work assessing skull TSPO PET signal before and after the establishment of a chronic pain condition (e.g., due to a surgery with a relatively high likelihood of chronic post-surgical pain, within the context of a preclinical pain model) will be needed to answer the question of causality. Also crucially, the focus of the current manuscript was not an analysis of the relationship between skull and brain inflammation, as a single metric suitable for quantifying the PET signal for both regions remains to be identified. Indeed, SUV is generally accepted for peripheral structures, but less so for quantification of the brain.

In conclusion, these findings indicate that increased immune activity in the skull bone marrow is linked to chronic pain and its associated symptoms. This highlights the emerging importance of skull bone marrow immunity in the development of chronic pain and possibly other conditions involving brain inflammation. Overall, these insights position the skull bone marrow as a crucial player in neuroimmune responses, with immune cell density in this area serving as a potential biomarker and therapeutic target for brain inflammation. These findings provide a strong rationale for investigating this previously overlooked structure, which remains largely underexplored in the context of pain.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Acknowledgements

The authors would like to acknowledge Erin J. Morrissey, Angel Torrado-Carvajal, Atreyi Saha, Paulina Knight, Chelsea Pike, Ava Axelrod, Erin Hardy, Yang Lin, Bang-Bon Koo for their help in data collection. Authors are also thankful to Grae Arabasz, Shirley Hsu, and the Athinoula A. Martinos Center for Biomedical Imaging Radiopharmacy team and imaging technologists for producing and administering the radioligand and assisting with the integrated PET-MR imaging.

Data sharing statement

Deidentified data may be shared with other researchers upon reasonable request.

References

1. Hadjikhani, N. *et al.* Extra-Axial Inflammatory Signal in Parameninges in Migraine with Visual Aura. *Ann Neurol* **87**, (2020).

2. Herisson, F. *et al.* Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. *Nat Neurosci* **21**, (2018).

3. Kolabas, Z. I. *et al.* Distinct molecular profiles of skull bone marrow in health and neurological disorders. *Cell* **186**, (2023).

4. Mazzitelli, J. A. *et al.* Skull bone marrow channels as immune gateways to the central nervous system. *Nat Neurosci* **26**, (2023).

5. Cugurra, A. *et al.* Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. *Science (1979)* **373**, (2021).

6. Liu, L. *et al.* Skull bone marrow and skull meninges channels: redefining the landscape of central nervous system immune surveillance. *Cell Death Dis* **16**, 53 (2025).

7. Zhou, R. *et al.* PET Imaging of Neuroinflammation in Alzheimer's Disease. *Frontiers in Immunology* vol. 12 Preprint at https://doi.org/10.3389/fimmu.2021.739130 (2021).

8. Gerhard, A. *et al.* In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. *Neurobiol Dis* **21**, 404–412 (2006).

9. Price, C. J. S. *et al.* Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. *Stroke* **37**, (2006).

10. Ramlackhansingh, A. F. *et al.* Inflammation after trauma: Microglial activation and traumatic brain injury. *Ann Neurol* **70**, 374–383 (2011).

11. Alshelh, Z. *et al.* In-vivo imaging of neuroinflammation in veterans with Gulf War illness. *Brain Behav Immun* **87**, 498–507 (2020).

12. Alshelh, Z. *et al.* Neuroimmune signatures in chronic low back pain subtypes. *Brain* **145**, 1098–1110 (2022).

13. Loggia, M. L. *et al.* Evidence for brain glial activation in chronic pain patients. *Brain* **138**, 604 (2015).

14. Loggia, M. L. "Neuroinflammation": does it have a role in chronic pain? Evidence from human imaging. *Pain* **165**, S58–S67 (2024).

15. Sandström, A. *et al.* [11C]-PBR28 positron emission tomography signal as an imaging marker of joint inflammation in knee osteoarthritis. *Pain* **165**, p 1121-1130 (2024).

16. Eiff, B. *et al.* Extra-axial inflammatory signal and its relationship to peripheral and central immunity in depression. *Brain* **148**, 635–646 (2025).

17. Tseng, C.-E. J., Guma, E., McDougle, C. J., Hooker, J. M. & Zürcher, N. R. Regional skull translocator protein elevation in autistic adults detected by PET-MRI. *Brain Behav Immun* **126**, 70–79 (2025).

18. Alshelh, Z. *et al.* Brain inflammation and its predictive value for post-operative pain in total knee arthroplasty patients. *Brain Behav Immun* **128**, 703–712 (2025).

19. Mohammadian, M. *et al.* Investigating the potential of minocycline in reducing brain inflammation in chronic low back pain: a randomized, placebo-controlled mechanistic clinical trial. *Pain* (9900).

20. Owen, D. R. *et al.* Two binding sites for 3 HPBR28 in human brain: Implications for TSPO PET imaging of neuroinflammation. *Journal of Cerebral Blood Flow and Metabolism* **30**, 1608–1618 (2010).

21. Owen, D. R. *et al.* An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. *Journal of Cerebral Blood Flow and Metabolism* **32**, 1–5 (2012).

22. Erdo□an, H. & Fessler, J. A. Ordered subsets algorithms for transmission tomography. *Phys Med Biol* **44**, (1999).

23. Izquierdo-Garcia, D. *et al.* An SPM8-based approach for attenuation correction combining segmentation and nonrigid template formation: Application to simultaneous PET/MR Brain Imaging. *Journal of Nuclear Medicine* **55**, (2014).

24. Catana, C. *et al.* Towards implementing an MR-based PET attenuation correction for neurological studies. in *IEEE Nuclear Science Symposium & Medical Imaging Conference* (2009).

25. Izquierdo-Garcia, D. *et al.* Comparison of MR-based attenuation correction and CT-based attenuation correction of whole-body PET/MR imaging. *Eur J Nucl Med Mol Imaging* **41**, (2014).

26. Fischl, B. FreeSurfer. *Neuroimage* **62**, 774–81 (2012).

27. Tustison, N. J. *et al.* The ANTsX ecosystem for quantitative biological and medical imaging. *Sci Rep* **11**, (2021).

28. Sorge, R. E. *et al.* Different immune cells mediate mechanical pain hypersensitivity in male and female mice. *Nat Neurosci* **18**, (2015).

29. Winkler, A. M., Ridgway, G. R., Webster, M. A., Smith, S. M. & Nichols, T. E. Permutation inference for the general linear model. (2014) doi:10.1016/j.neuroimage.2014.01.060.

30. Cai, R. *et al.* Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull–meninges connections. *Nat Neurosci* **22**, (2019).

31. Xanthos, D. N. & Sandkühler, J. Neurogenic neuroinflammation: Inflammatory CNS reactions in response to neuronal activity. *Nature Reviews Neuroscience* vol. 15 Preprint at https://doi.org/10.1038/nrn3617 (2014).

32. Koh, B. I. *et al*. Adult skull bone marrow is an expanding and resilient haematopoietic reservoir. *Nature* **636**, 172–181 (2024).

Figure Legends

Figure 1: Processing pipeline. T1-weighted structural MRI (A); Estimated pseudoCT image used for PET attenuation correction (B); Reconstructed 3D rendering of a subject's skull in native space after applying the heuristic threshold to extract the bone values (C), highlighting the pseudoCT method's ability to accurately recover the skull shape from the T1-weighted MRI, which is typically unable to visualize this structure; Reconstructed 3D rendering of the skull in standard MNI152 space (D); Reconstructed average 60-90 minute [^{11}C]PBR28 TSPO PET SUV (E); Skull [^{11}C]PBR28 TSPO PET overlaid on structural T1-weighted MRI in subject's native space (F); Skull [^{11}C]PBR28 TSPO PET normalized to the MNI152 space overlaid on standard structural MNI152 (G); Reconstructed 3D rendering of the skull TSPO PET SUV in standard MNI152 space (H). SUV: Standardized Uptake Value.

Figure 2: Average [^{11}C]PBR28 TSPO PET skull SUV from all patients with chronic pain and controls (A); 3D mapping of the voxels where the Pain group showed an elevated signal compared with healthy controls overlaid onto a 3D skull model in the standard MNI152 space (B); Box and scatter plots of the average significant voxels for each group (C). SUV: Standardized Uptake Value.

Figure 3: Average [^{11}C]PBR28 TSPO PET skull SUV maps by low, mid, and high tertiles of the pain intensity scores (A); 3D mapping of the voxels where patients with chronic pain showed a positive correlation between the TSPO PET signal and the PROMIS-29 pain intensity score overlaid onto a 3D skull model in the standard MNI152 space (B); Scatter plots with the fitted regression line and 95% confidence interval of the significant voxels, averaged for each subject, in patients by group (C). SUV: Standardized Uptake Value.

Figure 4: Average [^{11}C]PBR28 TSPO PET skull SUV maps by low, mid, and high tertiles of the pain interference scores (A); 3D mapping of the voxels where patients with chronic pain

showed a positive correlation between the TSPO PET signal and the PROMIS-29 pain interference score overlaid onto a 3D skull model in the standard MNI152 space (B); Scatter plots with the fitted regression line and 95% confidence interval of the significant voxels, averaged for each subject, in patients by group (C). SUV: Standardized Uptake Value.

Figure 5: 3D mapping of the voxels where patients with chronic pain showed a positive correlation between the TSPO PET signal and the PROMIS-29 anxiety and depression scores (A); Scatter plots with the fitted regression line and 95% confidence interval of the significant voxels, averaged for each subject, in patients by group (B). SUV: Standardized Uptake Value.

Table 1. Participant Demographics by Study Group

Variable	cLBP	KOA	cLBP + KOA "Pain group"	HC
N	88	37	125	22
Female, N(%)	52 (59.09)	16 (43.24)	68 (54.4)	11 (50)
Age, mean (SD)	47.32 (15.45)*†	66.59 (8.29)*	53.1 (16.38)	55.68 (16.89)
TSPO Genotype, N(%HAB)	54 (61.36)	21(56.76)	75 (60)	10 (45.45)
PROMIS-29 [0-20, except where specified], mean (SD)				
Pain intensity [0-10] ↑	4.17 (1.79)**	4.32 (2.54)**	4.22 (2.03)**	0.36 (0.66)
Pain interference ↑	8.85 (3.21)**†	11.08 (4.15)**	9.51 (3.64)**	4.00 (0)
Physical function ↓	12.64 (5.88)**	13.40 (3.65)**	12.86 (5.32)**	19.95 (0.21)
Anxiety ↑	6.79 (3.37)*	6.27 (2.13)	6.64 (3.05)*	5.22 (1.90)
Depression ↑	5.65 (2.59)*	4.97 (1.40)	5.45 (2.32)*	4.64 (1.29)
Fatigue ↑	9.06 (3.43)**	8.19 (2.56)**	8.80 (3.21)**	6.04 (1.84)
Sleep disturbance ↑	10.34 (3.67)**	10.08 (3.37)**	10.26 (3.57)**	6.86 (2.75)
Social roles ↓	12.11 (5.41)**	10.16 (4.15)**	11.54 (5.13)**	18.14 (2.47)

KOA, knee osteoarthritis; cLBP, chronic low back pain; HC, healthy controls; TSPO, 18 kDa translocator protein; HAB, high-affinity binder; SD, standard deviation;
Vs HC: *p<0.05, **p<0.001; cLBP Vs. KOA: †p<0.05; ↑/↓, directionality of worse outcome


A
B
C
D
E
F
G
H


A
Pain
HC
S
P
A
I
SUV
0.5
0
B
Pain > HC
S
A
L
R
P
A
A
zstat
5
3.1
C
[11C] PBR28 PET signal (SUV)
1.00
0.75
0.50
0.25
0.00
***
***
***
Healthy
Back pain
Knee pain
Healthy
Back pain
Knee pain


A
Pain intensity < 4
N = 51
4 ≤ Pain intensity < 6
N = 41
Pain Intensity ≥ 6
N = 33
SUV
0.5
0
S
P
A
I
B
S
A
L
R
P
A
A
zstat
5
3.1
C
Back pain (r=0.39)
Knee pain (r=0.56)
1.2
1.0
0.8
0.6
0.4
0.2
11[C]PBR28 PET signal (SUV)
0
2
4
6
8
PROMIS-29 Pain intensity


A
Pain interference < 8
N = 44
8 ≤ Pain interference < 12
N = 40
Pain interference ≥ 12
N = 41
SUV
0.5
0
S
P
A
I
B
S
A
L
R
zstat
5
3.1
P
A
A
C
Back pain (r=0.49)
Knee pain (r=0.36)
1.2
1.0
0.8
0.6
0.4
0.2
11[C]PBR28 PET signal (SUV)
4
6
8
10
12
14
16
18
20
PROMIS-29 Pain interference

A


Anxiety
Depression
S
A
L
R
P
A
zstat
5
3.1

B


Back pain (r=0.40)
Knee pain (r=0.48)
11[C]PBR28 PET signal (SUV)
PROMIS-29 Anxiety
Back pain (r=0.24)
Knee pain (r=0.51)
11[C]PBR28 PET signal (SUV)
PROMIS-29 Depression